Prescription Middlemen Could Be Making Your Healthcare More Expensive

Join our fight to bring more transparency and accountability to Pharmacy Benefit Managers. 

Stand with us, demand action against profit-focused PBMs. Let's prioritize patients' health, advocate for transparency, and fairness in healthcare. Using the tool below, you can enter your information and send a letter directly to your elected officials.

 

 

 

Important First Step Achieved to Hold PBMs Accountable

The “Lower Costs, More Transparency Act” passed the House with strong bipartisan support on December 11th. This is a vital step toward lowering healthcare costs and ensuring healthcare decisions are made by patients and doctors, not profit-driven middlemen. You helped make it happen.

Next step: The Senate takes up the issue.

PBMs and insurance companies work together to decide what medicines will be covered by insurance and the price of those drugs. While the concept was designed to help people save money, the largest 6 PBMs control almost 96% of the PBM market. The largest 3 (Optum, Express Scripts, and CVS Caremark) control 80% of that market. This gives PBMs inordinate power to set prices, deny coverage and pad their bottom line instead of passing the savings along to people who need medicine.

Your healthcare decisions should be made by you and your medical provider, not insurance companies and their prescription middlemen.

Easily send an email and/or Tweet to your elected officials urging them to pass PBM reform.

Latest from BIO.News
New studies highlight PBMs’ profit sources, customer dissatisfaction

As Congress, the U.S. Federal Trade Commission, and industry are taking a closer look at PBMs, a new report highlights the fact that a growing share of PBMs’ profits come from fees and specialty pharmacy ownership.

Congress puts PBMs in the spotlight during a busy week on Capitol Hill

The challenge of preventing pharmacy benefit managers (PBMs) from driving up drug prices was front and center on Capitol Hill this week.

Are PBMs working in the interest of health care – or themselves?

On May 23, the House Committee on Oversight and Accountability sought to answer this question: are PBMs working in the interest of health care, or themselves?

Latest from Good Day BIO Newsletter
How PBMs profit
Several new studies highlight the growing problem of PBMs—plus, Bio.News has an exclusive look at the growing “biotech sisterhood” and how women CEOs are helping women colleagues and patients. (550 words, 2 minutes, 45 seconds)
BIO Vice Chair to testify on price controls –…
A busy week on Capitol Hill continues with BIO Vice Chair John Crowley testifying on the Inflation Reduction Act’s price controls, and a recap of the bipartisan consensus on PBMs from yesterday. Plus, BIO SVP Phyllis Arthur will speak at UNGA in New…
4 PBMs dominate national market, says study
A new study highlights the scale of PBM concentration and its impact on patients. Planning to apply for SBIR/STTR grants? You don’t want to miss this upcoming opportunity to learn from grant-writing experts and NIH. (604 words, 3 minutes, 1 second)